Gastroenterology News

BOSTON — Nancy S. Reau, MD, FAASLD, AGAF, spoke with Healio about results from the END C study, which evaluated a community-based care model for hepatitis C virus infection among individuals at multiple community homeless sites in England.

BOSTON — In this video, Rohit Loomba, MD, MHSc, discusses data supporting once-monthly dosing of BOS-580, an investigational, long-acting fibroblast growth factor-21 analog for treatment of metabolic dysfunction-associated steatohepatitis.

Staying in a hospital room or bed previously occupied by someone with Clostridioides difficile nearly doubles a patient’s risk for hospital onset-C. difficile infection, researchers found.

Colorectal cancer incidence has increased since 1988 among men but not women younger than 50 years, suggesting that patient sex should be factored in when determining screening age, data from an Austrian study showed.

BOSTON — In this video, Nancy S. Reau, MD, FAASLD, AGAF, reviews three abstracts presented at The Liver Meeting related to pregnancy and pediatric treatments for hepatitis C virus infection.

In this Healio video exclusive, Dean Hum, PhD, chief scientific officer at Genfit, outlines five ongoing programs in the company’s acute-on-chronic liver failure development pipeline, which recently were presented at The Liver Meeting.

BOSTON — According to an abstract at The Liver Meeting, patients of Hispanic ethnicity who had elevated liver enzymes at baseline remained at increased risk for hepatocellular carcinoma, despite spontaneously clearing hepatitis C virus.

The PillSense System, a novel blood-sensing swallowed capsule device, safely detected blood in patients with clinically suspected upper gastrointestinal bleeding with a sensitivity of 92.9% and a specificity of 90.6%, data showed.

CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national commercial formularies effective April 1 in favor of biosimilar options, according to a press release from the company.

From a shift in nomenclature for steatotic liver disease to how a boom in live biotherapeutics will revamp treatment for Clostridioides difficile infection, Healio was at the forefront of gastroenterology and hepatology coverage in 2023.